[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201270818A1 - 6-(1-МЕТИЛ-1H-ПИРАЗОЛ-4-ИЛ)-3-(2-МЕТИЛ-2H-ИНДАЗОЛ-5-ИЛТИО)-[1,2,4]ТРИАЗОЛ-[43-b]ПИРИДАЗИН В КАЧЕСТВЕ ИНГИБИТОРА c-МЕТ - Google Patents

6-(1-МЕТИЛ-1H-ПИРАЗОЛ-4-ИЛ)-3-(2-МЕТИЛ-2H-ИНДАЗОЛ-5-ИЛТИО)-[1,2,4]ТРИАЗОЛ-[43-b]ПИРИДАЗИН В КАЧЕСТВЕ ИНГИБИТОРА c-МЕТ

Info

Publication number
EA201270818A1
EA201270818A1 EA201270818A EA201270818A EA201270818A1 EA 201270818 A1 EA201270818 A1 EA 201270818A1 EA 201270818 A EA201270818 A EA 201270818A EA 201270818 A EA201270818 A EA 201270818A EA 201270818 A1 EA201270818 A1 EA 201270818A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methyl
met
inhibitor
iltio
indazol
Prior art date
Application number
EA201270818A
Other languages
English (en)
Inventor
Чжипэй У
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201270818A1 publication Critical patent/EA201270818A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Изобретение относится к ингибитору c-Met (описанному в настоящей заявке) или его фармацевтически приемлемой соли, пригодной для лечения рака, опосредованного активностью рецепторов c-Met.
EA201270818A 2010-07-30 2011-07-22 6-(1-МЕТИЛ-1H-ПИРАЗОЛ-4-ИЛ)-3-(2-МЕТИЛ-2H-ИНДАЗОЛ-5-ИЛТИО)-[1,2,4]ТРИАЗОЛ-[43-b]ПИРИДАЗИН В КАЧЕСТВЕ ИНГИБИТОРА c-МЕТ EA201270818A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36933510P 2010-07-30 2010-07-30
PCT/US2011/044926 WO2012015677A1 (en) 2010-07-30 2011-07-22 6- (1-methyl-1h-pyrazol-4-yl)-3-(2-methyl-2h-indazol-5-

Publications (1)

Publication Number Publication Date
EA201270818A1 true EA201270818A1 (ru) 2013-05-30

Family

ID=44513148

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270818A EA201270818A1 (ru) 2010-07-30 2011-07-22 6-(1-МЕТИЛ-1H-ПИРАЗОЛ-4-ИЛ)-3-(2-МЕТИЛ-2H-ИНДАЗОЛ-5-ИЛТИО)-[1,2,4]ТРИАЗОЛ-[43-b]ПИРИДАЗИН В КАЧЕСТВЕ ИНГИБИТОРА c-МЕТ

Country Status (15)

Country Link
US (1) US8268836B2 (ru)
EP (1) EP2598144B1 (ru)
JP (1) JP5738412B2 (ru)
KR (1) KR20130052740A (ru)
CN (1) CN103002898A (ru)
AR (1) AR085183A1 (ru)
AU (1) AU2011282973B2 (ru)
BR (1) BR112013002211A2 (ru)
CA (1) CA2805494A1 (ru)
EA (1) EA201270818A1 (ru)
ES (1) ES2516940T3 (ru)
IN (1) IN2012MN02924A (ru)
MX (1) MX2013001247A (ru)
TW (1) TWI431008B (ru)
WO (1) WO2012015677A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9260531B2 (en) * 2012-05-09 2016-02-16 Eli Lilly And Company Anti-c-met antibodies
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
US10386376B2 (en) 2015-11-09 2019-08-20 Jeimei, Llc Sample container with integrated test strip
CN108853108A (zh) * 2015-12-31 2018-11-23 北京浦润奥生物科技有限责任公司 化合物在制备用于治疗脑胶质瘤的药物中的用途
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008007049A (es) * 2005-11-30 2008-10-23 Vertex Pharma Inhibidores de c-met y usos de los mismos.
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
CN101558070A (zh) * 2006-10-23 2009-10-14 Sgx药品公司 三唑并哒嗪蛋白激酶调节剂
DK2084162T3 (da) * 2006-10-23 2012-10-01 Sgx Pharmaceuticals Inc Bicykliske triazoler som proteinkinasemodulatorer
EP2081937B1 (en) 2006-10-23 2012-09-12 SGX Pharmaceuticals, Inc. Triazolopyridazine protein kinase modulators
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
BRPI0908504A2 (pt) 2008-02-28 2015-08-11 Novatis Ag Compostos derivados de 3-metil-imidazo[1,2-b]piridazina, uso dos mesmos e composição farmacêutica

Also Published As

Publication number Publication date
JP2013532687A (ja) 2013-08-19
ES2516940T3 (es) 2014-10-31
JP5738412B2 (ja) 2015-06-24
BR112013002211A2 (pt) 2016-05-24
KR20130052740A (ko) 2013-05-23
CA2805494A1 (en) 2012-02-02
WO2012015677A1 (en) 2012-02-02
US20120028984A1 (en) 2012-02-02
MX2013001247A (es) 2013-03-18
IN2012MN02924A (ru) 2015-06-12
EP2598144B1 (en) 2014-08-13
CN103002898A (zh) 2013-03-27
US8268836B2 (en) 2012-09-18
AU2011282973A1 (en) 2013-01-10
TW201219393A (en) 2012-05-16
AR085183A1 (es) 2013-09-18
TWI431008B (zh) 2014-03-21
EP2598144A1 (en) 2013-06-05
WO2012015677A9 (en) 2012-12-13
AU2011282973B2 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
EA201270818A1 (ru) 6-(1-МЕТИЛ-1H-ПИРАЗОЛ-4-ИЛ)-3-(2-МЕТИЛ-2H-ИНДАЗОЛ-5-ИЛТИО)-[1,2,4]ТРИАЗОЛ-[43-b]ПИРИДАЗИН В КАЧЕСТВЕ ИНГИБИТОРА c-МЕТ
EA201170872A1 (ru) Ингибиторы протеинкиназы
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
EA201491456A1 (ru) Соединения-ингибиторы raf
EP4219465A3 (en) Prmt5 inhibitors and uses thereof
MX2014001497A (es) Profarmacos de trepostinil enlazados a un portador.
EA201690752A1 (ru) Ингибиторы g12c kras
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
MX2019010446A (es) Compuestos de anillos fusionados biciclicos derivados de piridilo como inhibidores de fgfr4.
EA201991884A3 (ru) Ингибиторы g12c kras
BR112017019286A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável deste
TR201905814T4 (tr) Jak inhibitörü olarak bipirazol tuzu.
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
EA201590930A1 (ru) Лекарственные формы руксолитиниба с замедленным высвобождением
EA201591612A1 (ru) ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ
EA200970402A1 (ru) Триазолопиридазиновые модуляторы протеинкиназ
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
CR20130023A (es) Pirazolo[1,5-a]pirimidinas para tratamiento antiviral
CL2011001947A1 (es) Compuestos derivados de fenil-{1,2,4}triazolo[1,5-a]piridin-fenilamino sustituidos, inhibidores de cinasa; utiles para tratar trastornos asociados con la permeabilidad vascular.
BR112016029825A2 (pt) composto
MX2016007128A (es) Compuestos del receptor 6 de quimiocina (ccr6).
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
EA201591024A1 (ru) Димерные соединения
AR093527A1 (es) 6-((S)-1-1-[5-(2-HIDROXI-ETOXI)-PIRIDIN-2-IL]1H-PIRAZOL-3-IL-ETIL)-3H-1,3-BENZOTIAZOL-2-ONA COMO UN ANTAGONISTA DEL RECEPTOR AMPA DEPENDIENTE DE TARP-g 8
UY33976A (es) Derivados de pirazolo-pirimidina.